GSK, GB0009252882

British American Tobacco plc stock (GB0009252882): BTI surges 9.2% to $63.64

13.05.2026 - 17:00:15 | ad-hoc-news.de

British American Tobacco PLC (BTI) shares jumped 9.2% on May 12, 2026, reaching $63.64 amid positive market sentiment. Fitch Ratings highlighted the company's strengthened business profile with global scale and next-gen product growth.

GSK, GB0009252882
GSK, GB0009252882

British American Tobacco PLC (BTI) shares rose 9.2% on May 12, 2026, closing at $63.64, according to GuruFocus as of 05/12/2026. This notable gain stands out in the tobacco sector, driven by broader market dynamics and analyst upgrades. Fitch Ratings upgraded BAT's business profile on May 13, 2026, citing global diversification and high growth in next-generation products, per Fitch Ratings as of 05/13/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

  • Name: British American Tobacco p.l.c.
  • Sector/industry: Tobacco
  • Headquarters/country: United Kingdom
  • Core markets: Global
  • Key revenue drivers: Cigarettes, next-gen products
  • Home exchange/listing venue: NYSE (BTI), LSE (BATS.L)
  • Trading currency: USD, GBP

Official source

For first-hand information on British American Tobacco plc, visit the company’s official website.

Go to the official website

British American Tobacco plc: core business model

British American Tobacco plc operates as a multinational tobacco company, producing and selling cigarettes and other nicotine products worldwide. Its portfolio includes leading brands like Lucky Strike, Dunhill, and Kent, alongside growing next-generation products such as Vuse vaping devices and Velo oral nicotine pouches. The company focuses on transitioning smokers to reduced-risk products while maintaining combustible cigarette volumes in key markets.

With operations in over 180 countries, British American Tobacco plc generates revenue through a diversified geographic footprint, including strong positions in the US, Europe, and emerging markets. This global scale provides resilience against regional regulatory pressures, a factor noted in recent Fitch assessments.

Main revenue and product drivers for British American Tobacco plc

Combustible tobacco remains the primary revenue driver, accounting for the majority of sales as of the latest reported periods. Next-generation products (NGP) showed robust growth, with high potential highlighted by Fitch on May 13, 2026. In the US, brands like Vuse hold significant market share in the e-vapor category, appealing to US investors via NYSE listing (BTI).

Dividend yield stands at 5.66% as tracked by MarketBeat data as of 05/2026, positioning it among top payers. On LSE (BATS.L), the stock traded at 3,900.00p on July 25, 2025, per StockInvest.us as of 07/25/2025, reflecting ongoing volatility.

Industry trends and competitive position

The tobacco industry faces regulatory scrutiny but benefits from NGP innovation. British American Tobacco plc's global diversification and brand strength give it a competitive edge over peers. US exposure via BTI makes it relevant for American portfolios seeking yield in defensive sectors.

Read more

Additional news and developments on the stock can be explored via the linked overview pages.

More news on this stockInvestor relations

Conclusion

British American Tobacco plc continues to navigate industry challenges with strong global positioning and NGP momentum, as evidenced by the recent 9.2% BTI gain and Fitch upgrade. US investors track its NYSE performance amid yield appeal and regulatory developments. Market dynamics remain fluid with focus on diversification.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

So schätzen die Börsenprofis GSK Aktien ein!

<b>So schätzen die Börsenprofis  GSK Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
en | GB0009252882 | GSK | boerse | 69325565 |